Merck's Mixed Financial Outlook Despite Rising Product Sales

Merck & Co reported a financial loss for the first quarter due to acquisition charges, despite a 5% increase in product sales. The company's revenue rose to $16.3 billion, beating Wall Street expectations. Merck's future profit forecasts include impacts from its planned acquisitions.

Merck & Co faced financial challenges in the first quarter as acquisition-related charges overshadowed a 5% rise in product sales, primarily driven by cancer and respiratory drugs.

Despite this setback, the U.S. drugmaker's revenue climbed to $16.3 billion from $15.5 billion the previous year, surpassing Wall Street's $15.8 billion forecast. The company's adjusted loss, factoring in the $3.62 per share charge for acquiring antiviral drugmaker Cidara Therapeutics, was $1.28 per share, against analysts' expectations of $1.51 per share.

Looking ahead, Merck provided an updated annual forecast, adjusting its profit estimates to $5.04 to $5.16 per share on sales between $65.8 billion and $67 billion. This does not account for the acquisition of Terns Pharmaceuticals, expected to cause a $2.35 per share charge. Keytruda, a leading prescription drug, posted a 12% sales increase, reaching $8 billion, while sales of other drugs like Winrevair and Januvia experienced mixed results.